Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

von, Lewinski, D; Tripolt, NJ; Sourij, H; Pferschy, PN; Oulhaj, A; Alber, H; Gwechenberger, M; Martinek, M; Seidl, S; Moertl, D; Nürnberg, M; Roithinger, FX; Steinwender, C; Stühlinger, M; Zirlik, A; Benedikt, M; Kolesnik, E; Wallner, M; Rohrer, U; Manninger, M; Scherr, D, , ERASe, study, group.
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study.
Am Heart J. 2022; 246:152-160 Doi: 10.1016/j.ahj.2022.01.008
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
von Lewinski Dirk
Co-Autor*innen der Med Uni Graz
Benedikt Martin
Kolesnik Ewald
Manninger-Wünscher Martin
Pferschy Peter
Rohrer Ursula
Scherr Daniel
Sourij Harald
Tripolt Norbert
Wallner Markus
Zirlik Andreas

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These effects are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties are discussed as underlying mechanisms. Despite a strong correlation of ventricular arrhythmias with HFrEF, the impact of ertugliflozin on the ventricular arrhythmic burden has not been investigated, yet. Therefore, the Ertugliflozin to Reduce Arrhythmic burden in ICD ± CRT patientS (ERASe) trial was designed to investigate the efficacy and safety of ertugliflozin in patients with reduced and midrange ejection fraction (EF) with or without diabetes. METHODS: Within a multicentre, national, randomized, double-blind, placebo-controlled, phase 3b trial we aim to enrol a total of 402 patients across Austria. Patients with reduced or midrange EF and ICD ± CRT therapy >3 months and previous ventricular tachycardia (at least 10 documented VT episodes within the last 12 months) are randomized in a 1:1 ratio to ertugliflozin (5 mg once daily orally administered) or matching placebo. The primary endpoint of the ERASe trial is to investigate the impact of ertugliflozin on total burden of ventricular arrhythmias. Further objectives will include number of therapeutic interventions of implanted devices, atrial fibrillation and heart failure biomarkers. CONCLUSION: The ERASe trial will be the first trial to test ertugliflozin in heart failure patients with nonpreserved ejection fraction and ongoing ICD ± CRT therapy regardless of their diabetic status. The ERASe trial may therefore extend the concept of SGLT2 inhibition to improve cardiac remodelling, including reduced arrhythmic burden. Trial registration Identifier EudraCT Nr. 2020-002581-14 / Identifier: NCT04600921.

© Med Uni Graz Impressum